Brand Name: LAZCLUZE Generic Name: lazertinib LAZCLUZE (lazertinib) is used to treat non-small cell lung cancer (NSCLC) .
LAZCLUZE is prescription medicines. On August 19, 2024, the Food and Drug Administration approved lazertinib (Lazcluze, Janssen Biotech, Inc.) in combination with amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC).
| Brand Name: | LAZCLUZE |
| Generic Name: | lazertinib |
| Strength: | Tablets: 80 mg and 240 mg |
| Manufacturer: | Janssen Biotech |
| Approved By: | EMA, USFDA |
Source Details: Patient Information
IPN, New Delhi can facilitate patient to import of “LAZCLUZE (lazertinib)” in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP). If you have any question, please email IPN healthcare Support Team for LAZCLUZE (lazertinib) price list or cost in India. on Mr. Tarun:- +91 9891 296 838 / Mr. Neeraj:- +91 9811 747 774.
